FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach – CNBC

FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach CNBCFDA approves first RSV vaccine for at-risk adults in their 50s CBS NewsGSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use MarketWatchGSK RSV Vaccine Wins US Approval for Younger Age Group BloombergGSK exec lauds ‘great start’ to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 FiercePharma